幽门螺杆菌
克拉霉素
噬菌体疗法
抗生素
阿莫西林
胃炎
溶解循环
微生物学
医学
螺杆菌
抗生素耐药性
慢性胃炎
致病菌
细菌
病毒学
胃肠病学
生物
噬菌体
病毒
基因
遗传学
大肠杆菌
作者
Filipa F. Vale,António Matos,P.A. Carvalho,Jorge M. B. Vítor
标识
DOI:10.1017/s1431927608089721
摘要
Helicobacter pylori is a helical shaped Gram-negative bacterium that colonizes the human stomach. It is associated with several human pathologies, such as gastritis, peptic ulcer, and gastric cancer. The standard first-line treatment is a one week triple therapy: the association of two antibiotics, most frequently amoxicillin and clarithromycin, and a proton pump inhibior. Despite the evolution of the treatment strategy, quadruple therapy, there is an increasing percentage of failure of the antibiotic therapy, due to antibiotics resistance. Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections and H. pylori is a good target. However there are no available phage collections, and H. pylori phages description is diminutive on literature.
科研通智能强力驱动
Strongly Powered by AbleSci AI